|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 13X微孔沸石和MCM-41介孔材料的合成及用于处理含Cd^(2+)废水显示文摘以天津蓟县钾长石矿粉为主要原料,经选矿、煅烧、水热处理等工艺成功合成了13X微孔沸石.以气相氧化硅、氢氧化钠、十六烷基三甲基溴化铵等为主要原料,在水热条件下合成了MCM-41有序介孔材料.采用XRD和N_2吸附-脱附等手段对合成的13X沸石和MCM-41介孔材料的物相、比表面积、孔径、孔体积等进行了分析对比.在此基础上,对13X沸石和MCM-41介孔材料处理含Cd^(2+)废水的效果和机理进行了对比研究,确定了不同分子筛用量、不同初始pH值、不同混合时间下13X沸石和MCM-41介孔分子筛对水中Cd^(2+)的吸附率和吸附量.研究发现,尽管MCM-41的比表面积和孔径远大于13X沸石,但其对水中Cd^(2+)的处理效果却低于13X沸石,这与13X沸石和MCM-41的孔道结构类型、化学组成、表面荷电性质等有关. | 杨静 麻晓光 马鸿文 Ray L.Frost | 2007 | 过程工程学报2007，7，2： | 9 |
| 2 | HDTMAB改性蒙脱石对苯酚的吸附实验研究显示文摘以阳离子表面活性剂十六烷基三甲基溴化铵(HDTMAB)为柱撑剂对怀俄明钠基蒙脱石进行改性,获得了不同质量浓度的有机改性黏土(0.5~2.5CEC)。通过对改性蒙脱石吸附苯酚的XRD、TEM和热重分析的实验研究,发现改性后蒙脱石的层间距明显增大。实验结果表明随着改性活性剂质量浓度的加大,HDTMAB有机离子逐渐由单层变为双层直至三层。有机蒙脱石去除水溶液中苯酚的能力也相应地得到了很大的提高,吸附效果明显增强。 | 刘瑞 王志华 Ray L.Frost | 2010 | 长春工程学院学报(自然科学版)2010，11，3： | 3 |
| 3 | 氧化硅有序介孔材料MCM-41的微波水热合成及用于组装ZnO纳米粒子显示文摘与传统水热合成工艺相比,采用微波水热合成新工艺可以快速合成比表面积大、孔体积和孔径大、孔径分布范围更窄、孔洞呈六方排布的有序介孔材料MCM-41.微波水热合成工艺合成的MCM-41具有合成效率高、成功率高等特点,为此类介孔材料商业化提供了高效的技术手段.采用传统水热工艺合成MCM-41通常需要48~72h,而采用微波水热合成技术仅需要30min.采用X射线粉晶衍射(XRD),氮气吸附等技术手段对合成MCM-41材料的物相、比表面积、孔体积、孔径等进行了表征.采用微波水热合成MCM-41的工艺参数为:微波处理的温度120℃,时间30min,微波辐射功率500W,经过滤、洗涤、干燥、焙烧等处理后,得到的MCM-41具有六方排布的孔系,晶格常数a0=4.4nm,比表面积可达1113m2/g,平均孔径为2.7nm,与选用同样配方采用传统水热合成工艺合成的MCM-41的性能相当,却极大提高了合成效率.采用微波水热合成工艺,同样可以合成立方晶系的MCM-48和六方晶系的SBA-15等介孔氧化硅分子筛材料.此外,在微波合成的MCM-41中采用液相工艺成功组装了ZnO纳米粒子,并对组装在MCM-41中的纳米ZnO粒子进行了光催化降解苯酚的实验研究. | 杨静 陶红 马鸿文 Ray L.Frost | 2006 | 过程工程学报2006，6，z2： | 2 |
| 4 | Synthe-sis,characterization of mono,di and tri alkyl surfactant intercalated Wyoming montmorillonite for the removal of phenol from aqueous systems显示文摘 | Rui Liu Ray L.Frost Wayde N.Martens | | 0，，02： | 1 |
| 5 | Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity显示文摘Disease-mediated alterations to drug disposition constitute a significant source of adverse drug reactions.Cisplatin(CDDP)elicits nephrotoxicity due to exposure in proximal tubule cells during renal secretion.Alterations to renal drug transporter expression have been discovered during nonalcoholic steatohepatitis(NASH),however,associated changes to substrate toxicity is unknown.To test this,a methionine-and choline-deficient diet-induced rat model was used to evaluate NASH-associated changes to CDDP pharmacokinetics,transporter expression,and toxicity.NASH rats administered CDDP(6 mg/kg,i.p.)displayed 20%less nephrotoxicity than healthy rats.Likewise,CDDP renal clearance decreased in NASH rats from 7.39 to 3.83 mL/min,renal secretion decreased from 6.23 to 2.80 mL/min,and renal CDDP accumulation decreased by 15%,relative to healthy rats.Renal copper transporter-1 expression decreased,and organic cation transporter-2 and ATPase copper transporting protein-7 b increased slightly,reducing CDDP secretion.Hepatic CDDP accumulation increased 250%in NASH rats relative to healthy rats.Hepatic organic cation transporter-1 induction and multidrug and toxin extrusion protein-1 and multidrug resistance-associated protein-4 reduction may contribute to hepatic CDDP sequestration in NASH rats,although no drug-related toxicity was observed.These data provide a link between NASH-induced hepatic and renal transporter expression changes and CDDP renal clearance,which may alter nephrotoxicity. | Joseph L.Jilek Kayla L.Frost Kevyn A.Jacobus Wenxi He Erica L.Toth Michael Goedken Nathan J.Cherrington | 2021 | Acta Pharmaceutica Sinica B2021，11，12： | 1 |
| 6 | Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in nonalcoholic steatohepatitis patients显示文摘The liver plays a central role in the pharmacokinetics of drugs through drug metabolizing enzymes and transporters.Non-alcoholic steatohepatitis(NASH)causes disease-specific alterations to the absorption,distribution,metabolism,and excretion(ADME)processes,including a decrease in protein expression of basolateral uptake transporters,an increase in efflux transporters,and modifications to enzyme activity.This can result in increased drug exposure and adverse drug reactions(ADRs).Our goal was to predict drugs that pose increased risks for ADRs in NASH patients.Bibliographic research identified 71 drugs with reported ADRs in patients with liver disease,mainly non-alcoholic fatty liver disease(NAFLD),54 of which are known substrates of transporters and/or metabolizing enzymes.Since NASH is the progressive form of NAFLD but is most frequently undiagnosed,we identified other drugs at risk based on NASH-specific alterations to ADME processes.Here,we present another list of 71 drugs at risk of pharmacokinetic disruption in NASH,based on their transport and/or metabolism processes.It encompasses drugs from various pharmacological classes for which ADRs may occur when used in NASH patients,especially when eliminated through multiple pathways altered by the disease.Therefore,these results may inform clinicians regarding the selection of drugs for use in NASH patients. | Solène Marie Kayla L.Frost Raymond K.Hau Lucy Martinez-Guerrero Jailyn M.Izu Cassandra M.Myers Stephen H.Wright Nathan J.Cherrington | 2023 | Acta Pharmaceutica Sinica B2023，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员